[go: up one dir, main page]

WO2008131575A3 - Anticorps anti-alk adaptés au traitement des cancers et tumeurs métastatiques - Google Patents

Anticorps anti-alk adaptés au traitement des cancers et tumeurs métastatiques Download PDF

Info

Publication number
WO2008131575A3
WO2008131575A3 PCT/CH2008/000193 CH2008000193W WO2008131575A3 WO 2008131575 A3 WO2008131575 A3 WO 2008131575A3 CH 2008000193 W CH2008000193 W CH 2008000193W WO 2008131575 A3 WO2008131575 A3 WO 2008131575A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumors
metastatic cancers
antibodies suitable
treating metastatic
alk antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CH2008/000193
Other languages
English (en)
Other versions
WO2008131575A2 (fr
Inventor
Der Maur Adrian Auf
Alcide Barberis
Peter Lichtlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esbatech a Novartis Co LLC
Original Assignee
Esbatech AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech AG filed Critical Esbatech AG
Publication of WO2008131575A2 publication Critical patent/WO2008131575A2/fr
Publication of WO2008131575A3 publication Critical patent/WO2008131575A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un anticorps spécifique pour l'ALK (kinase de lymphome anaplastique) humaine, en particulier un scFv, une séquence d'acide nucléique le codant, sa production et son utilisation à des fins pharmaceutiques ou diagnostiques. Ledit anticorps est adapté au traitement local de tumeurs, par exemple, le cancer ou les tumeurs métastatiques, en particulier le glioblastome.
PCT/CH2008/000193 2007-04-27 2008-04-28 Anticorps anti-alk adaptés au traitement des cancers et tumeurs métastatiques Ceased WO2008131575A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92681007P 2007-04-27 2007-04-27
US60/926,810 2007-04-27

Publications (2)

Publication Number Publication Date
WO2008131575A2 WO2008131575A2 (fr) 2008-11-06
WO2008131575A3 true WO2008131575A3 (fr) 2009-01-29

Family

ID=39926146

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CH2008/000193 Ceased WO2008131575A2 (fr) 2007-04-27 2008-04-28 Anticorps anti-alk adaptés au traitement des cancers et tumeurs métastatiques

Country Status (1)

Country Link
WO (1) WO2008131575A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2843158A1 (fr) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Anticorps bispecifiques a fc en tandem
TW201444872A (zh) 2013-03-06 2014-12-01 Merrimack Pharmaceuticals Inc 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體
WO2014159074A1 (fr) * 2013-03-12 2014-10-02 Five Prime Therapeutics, Inc. Antagonistes fam150a, fam150b et fam150 et leurs utilisations
EP3341021A4 (fr) * 2015-08-27 2019-03-13 Celldex Therapeutics, Inc. Anticorps anti-alk et leurs procédés d'utilisation
EP4334354A1 (fr) * 2021-05-06 2024-03-13 Dana-Farber Cancer Institute, Inc. Anticorps anti-alk et leurs procédés d'utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097697A2 (fr) * 2002-05-22 2003-11-27 Esbatech Ag Infrastructures immunoglobuliniques faisant preuve de stabilité accrue en environnement intracellulaire, et procédés d'identification correspondants
WO2007059300A2 (fr) * 2005-11-15 2007-05-24 Medimmune, Inc. Antagonistes et agonistes d'alk et applications
WO2007124610A1 (fr) * 2006-04-28 2007-11-08 Esbatech Ag Anticorps se liant au domaine extracellulaire du récepteur tyrosine kinase alk

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097697A2 (fr) * 2002-05-22 2003-11-27 Esbatech Ag Infrastructures immunoglobuliniques faisant preuve de stabilité accrue en environnement intracellulaire, et procédés d'identification correspondants
WO2007059300A2 (fr) * 2005-11-15 2007-05-24 Medimmune, Inc. Antagonistes et agonistes d'alk et applications
WO2007124610A1 (fr) * 2006-04-28 2007-11-08 Esbatech Ag Anticorps se liant au domaine extracellulaire du récepteur tyrosine kinase alk

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MOOG-LUTZ CHRISTEL ET AL: "Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 280, no. 28, 1 July 2005 (2005-07-01), pages 26039 - 26048, XP002424604, ISSN: 0021-9258 *
MOTEGI AKIRA ET AL: "ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth", JOURNAL OF CELL SCIENCE, CAMBRIDGE UNIVERSITY PRESS, LONDON, GB, vol. 117, no. 15, 1 July 2004 (2004-07-01), pages 3319 - 3329, XP002424605, ISSN: 0021-9533 *
POWERS CIARAN ET AL: "Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 16, 19 April 2002 (2002-04-19), pages 14153 - 14158, XP002503924, ISSN: 0021-9258 *
STOICA GERALD E ET AL: "Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 277, no. 39, 27 September 2002 (2002-09-27), pages 35990 - 35998, XP002290577, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2008131575A2 (fr) 2008-11-06

Similar Documents

Publication Publication Date Title
WO2007109321A3 (fr) Anticorps modifiés dirigés contre l'antigène de cellules souches prostatiques servant à cibler le cancer
PH12018550164A1 (en) Bcma binding molecules and methods of use thereof
WO2008066691A3 (fr) Tes7, et anticorps se liant à celui-ci
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2009032949A3 (fr) Anticorps d'antigène de cellule souche anti-prostate (psca) à haute affinité pour un ciblage et une détection de cancer
WO2008140493A3 (fr) Anticorps de la famille anti-egfr, anticorps de la famille anti-egfr bispécifiques et leurs procédés d'utilisation
CY1118693T1 (el) Αντισωματα αντι-ακτιβινης α και χρησεις αυτων
WO2005097832A3 (fr) Anticorps anti-tgf-$g(b) humanises
NZ704295A (en) Compositions and methods for the treatment of infections and tumors
WO2007084181A3 (fr) Molécules d'anticorps fv à chaîne unique bispécifiques et procédés d'utilisation de celles-ci
WO2007013950A3 (fr) Polytherapie de tumeurs exprimant her
WO2004058171A3 (fr) Anticorps anti-gpr64 et utilisations
UA95068C2 (uk) Антиген-зв'язуюча молекула, яка зв'язує еgfr, вектор, що її кодує, та їх застосування
WO2006083971A3 (fr) Anticorps dr5 et utilisations de ceux-ci
AU2006226897B2 (en) Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors
BRPI0916138A2 (pt) "método de tratamento de um sujeito diagnosticado com câncer de mama localmente, kit para tratar câncer de mama metastático em um sujeito humano, uso de um anticorpo antivegf na fabricação de um medicamento para tratar câncer de mama localmente recidivado ou metastático em um sujeito e anticorpo anti-vegf para uso em um método de tratamento de câncer de mama localmente recidivado ou metastático em um sujeito"
WO2006084075A3 (fr) Modulateurs adam-9
WO2007141280A3 (fr) protéines
WO2008151819A3 (fr) Traitement de tumeurs à l'aide d'un anticorps anti-l1 spécifique
WO2019234241A8 (fr) Anticorps anti-oxmif/anti-cd3 pour le traitement de cancers
WO2007135546A3 (fr) TRAITEMENT DU CANCER PAR DES ANTICORPS ANTI-IL-1α
WO2009004484A3 (fr) Modulateur de p53 et cible cancereuse
WO2006084078A3 (fr) Antigene jam-3 et anticorps se liant a celui-ci
WO2008136848A3 (fr) Nouveaux anticorps anti-notch3 et leur utilisation dans la détection et le diagnostic d'une maladie
MA32288B1 (fr) Nouveaux anticorps utiles pour le traitement du cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08733819

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08733819

Country of ref document: EP

Kind code of ref document: A2